Zimmer Biomet Holdings, Inc. has established two new revolving credit agreements: a five-year facility for $1.5 billion and a 364-day facility for $1.25 billion. These new agreements, effective June 26, 2026, replace the company's previous credit facilities dated June 27, 2025. The new five-year facility matures on June 26, 2031, with options for two one-year extensions, and includes an uncommitted feature to increase the facility by up to $750 million. The 364-day facility matures on June 25, 2027. Both facilities are unsecured and will be used for general corporate purposes. Interest rates for borrowings will be based on adjusted Term SOFR or an alternate base rate, plus an applicable margin tied to the company's senior unsecured long-term debt credit rating. The company will pay a facility fee based on its credit rating. Both agreements include customary covenants and events of default, with a requirement to maintain a consolidated indebtedness to consolidated EBITDA ratio of no greater than 4.5 to 1.0 (which can increase to 5.0 to 1.0 in certain acquisition scenarios). The previous credit agreements were terminated on June 26, 2026, with no outstanding principal balance. Approximately $0.4 million in fees were paid under the prior five-year agreement. Existing letters of credit under the old five-year agreement have been transitioned to the new five-year agreement.